ATE473974T1 - Pyrrolopyridin-2-carbonsäuren als hemmer der glycogenphosphorylase - Google Patents

Pyrrolopyridin-2-carbonsäuren als hemmer der glycogenphosphorylase

Info

Publication number
ATE473974T1
ATE473974T1 AT04753127T AT04753127T ATE473974T1 AT E473974 T1 ATE473974 T1 AT E473974T1 AT 04753127 T AT04753127 T AT 04753127T AT 04753127 T AT04753127 T AT 04753127T AT E473974 T1 ATE473974 T1 AT E473974T1
Authority
AT
Austria
Prior art keywords
inhibitors
glycogen phosphorylase
pyrrolopyridine
carbonic acids
cardioprotectants
Prior art date
Application number
AT04753127T
Other languages
English (en)
Inventor
Stuart Bradley
Thomas Krulle
Peter Murray
Martin Procter
Robert Rowley
Smith Colin Sambrook
Gerard Thomas
Karen Schofield
Original Assignee
Prosidion Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Prosidion Ltd filed Critical Prosidion Ltd
Application granted granted Critical
Publication of ATE473974T1 publication Critical patent/ATE473974T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Diabetes (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Endocrinology (AREA)
  • Cardiology (AREA)
  • Emergency Medicine (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Pyrrole Compounds (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Plural Heterocyclic Compounds (AREA)
AT04753127T 2003-05-21 2004-05-20 Pyrrolopyridin-2-carbonsäuren als hemmer der glycogenphosphorylase ATE473974T1 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US47237503P 2003-05-21 2003-05-21
US55125604P 2004-03-08 2004-03-08
PCT/US2004/016243 WO2004104001A2 (en) 2003-05-21 2004-05-20 Pyrrolopyridine-2-carboxylic acid amide inhibitors of glycogen phoshorylase

Publications (1)

Publication Number Publication Date
ATE473974T1 true ATE473974T1 (de) 2010-07-15

Family

ID=33479321

Family Applications (1)

Application Number Title Priority Date Filing Date
AT04753127T ATE473974T1 (de) 2003-05-21 2004-05-20 Pyrrolopyridin-2-carbonsäuren als hemmer der glycogenphosphorylase

Country Status (16)

Country Link
EP (1) EP1636224B1 (de)
JP (2) JP2006528702A (de)
KR (1) KR101120935B1 (de)
AT (1) ATE473974T1 (de)
AU (1) AU2004240946B8 (de)
BR (1) BRPI0410445B1 (de)
CA (1) CA2525502C (de)
DE (1) DE602004028122D1 (de)
EA (1) EA009215B1 (de)
IL (1) IL171851A (de)
MA (1) MA27809A1 (de)
MX (1) MXPA05012547A (de)
NO (1) NO332265B1 (de)
NZ (1) NZ543482A (de)
UA (1) UA84146C2 (de)
WO (1) WO2004104001A2 (de)

Families Citing this family (34)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0205175D0 (en) 2002-03-06 2002-04-17 Astrazeneca Ab Chemical compounds
GB0205166D0 (en) 2002-03-06 2002-04-17 Astrazeneca Ab Chemical compounds
CA2545644C (en) * 2003-11-12 2011-11-01 Lg Life Sciences Ltd. Melanocortin receptor agonists
ES2353309T3 (es) 2004-03-08 2011-03-01 Prosidion Ltd. Hidrazidas del ácido pirrolopiridin-2-carboxílico como inhibidores de glucógeno fosforilasa.
JP2007531744A (ja) * 2004-04-05 2007-11-08 武田薬品工業株式会社 ６−アザインドール化合物
DE102004054634A1 (de) * 2004-11-12 2006-05-18 Schwarz Pharma Ag Azaindolcarboxamide
GB0425919D0 (en) * 2004-11-25 2004-12-29 Prosidion Ltd Indole-2-carboxylic acid amides
PL1819704T3 (pl) 2004-12-02 2008-12-31 Prosidion Ltd Amidowe pochodne kwasu pirolopirydyno-2-karboksylowego użyteczne jako inhibitory fosforylazy glikogenowej
WO2006059163A1 (en) * 2004-12-02 2006-06-08 Prosidion Limited Treatment of diabetes with glycogen phosphorylase inhibitors
ATE424821T1 (de) 2004-12-02 2009-03-15 Prosidion Ltd Pyrrolopyridin-2-karbonsäureamide
EP1948597A1 (de) * 2005-10-21 2008-07-30 Vertex Pharmaceuticals Incorporated Derivate zur modulation von ionenkanälen
JP2009519293A (ja) * 2005-12-16 2009-05-14 エフ．ホフマン−ラ ロシュ アーゲー Ｈ３レセプター調節剤としてのピロロ［２，３−ｂ］ピリジン誘導体
PE20080251A1 (es) 2006-05-04 2008-04-25 Boehringer Ingelheim Int Usos de inhibidores de dpp iv
EP2089023A2 (de) 2006-11-02 2009-08-19 Aestus Therapeutics, Inc. Ppar-gamma-agonisten zur behandlung neuropathischer schmerzen
FR2911605B1 (fr) 2007-01-19 2009-04-17 Sanofi Aventis Sa Derives de pyrrolopyridine-2-carbowamides, leur preparation et leur application en therapeutique
DE102007012284A1 (de) 2007-03-16 2008-09-18 Boehringer Ingelheim Pharma Gmbh & Co. Kg Neue substituierte Arylsulfonylglycine, deren Herstellung und deren Verwendung als Arzneimittel
DE102007035334A1 (de) 2007-07-27 2009-01-29 Boehringer Ingelheim Pharma Gmbh & Co. Kg Neue substituierte Arylsulfonylglycine, deren Herstellung und deren Verwendung als Arzneimittel
DE102007035333A1 (de) 2007-07-27 2009-01-29 Boehringer Ingelheim Pharma Gmbh & Co. Kg Neue substituierte Arylsulfonylglycine, deren Herstellung und deren Verwendung als Arzneimittel
DE102007042154A1 (de) 2007-09-05 2009-03-12 Boehringer Ingelheim Pharma Gmbh & Co. Kg Arylsulfonylaminomethyphosphonsäure-Derivate, deren Herstellung und deren Verwendung als Arzneimittel
US8785489B2 (en) 2008-10-17 2014-07-22 Boehringer Ingelheim International Gmbh Heteroaryl substituted indole compounds useful as MMP-13 inhibitors
UY32940A (es) 2009-10-27 2011-05-31 Bayer Cropscience Ag Amidas sustituidas con halogenoalquilo como insecticidas y acaricidas
AR086554A1 (es) 2011-05-27 2014-01-08 Novartis Ag Derivados de la piperidina 3-espirociclica como agonistas de receptores de la ghrelina
WO2012166389A1 (en) 2011-05-31 2012-12-06 Theravance, Inc. Neprilysin inhibitors
CA2835220A1 (en) 2011-05-31 2012-12-06 Theravance, Inc. Neprilysin inhibitors
US8513244B2 (en) 2011-05-31 2013-08-20 Theravance, Inc. Neprilysin inhibitors
US9345247B2 (en) 2012-08-17 2016-05-24 Bayer Cropscience Ag Azaindole carboxylic acid amides and azaindole thiocarboxylic acid amides for use as insecticides and acaricides
CN103626825B (zh) * 2013-09-30 2015-10-07 承德医学院 靶向肝脏的糖原磷酸化酶抑制剂胆酸类衍生物、其制备方法及医药用途
CN105829296A (zh) 2013-12-18 2016-08-03 巴斯夫欧洲公司 带有亚胺衍生的取代基的唑类化合物
JP7805583B2 (ja) * 2019-11-27 2026-01-26 国立研究開発法人理化学研究所 Ｇ９ａ阻害剤
EP4237423B1 (de) 2020-11-02 2024-12-11 Boehringer Ingelheim International GmbH Substituierte 1h-pyrazolo[4,3-c]pyridine und derivate als egfr-inhibitoren
CA3211571A1 (en) * 2021-03-10 2022-09-15 Donna L. Romero Usp30 inhibitors and uses thereof
WO2023165168A1 (zh) * 2022-10-27 2023-09-07 常州大学 吡唑类衍生物作为β2肾上腺素受体别构调节剂,拮抗剂和激动剂的应用
CN115745891B (zh) * 2022-11-10 2025-08-01 常州大学 吡唑衍生物在作为β2-肾上腺素受体拮抗剂的应用
CN115894373B (zh) * 2022-10-27 2025-08-01 常州大学 N-取代苄基吡唑衍生物在作为β2肾上腺素受体调节剂、拮抗剂和激动剂的应用

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4619915A (en) * 1984-10-19 1986-10-28 Pfizer Inc. Peptide-substituted heterocyclic immunostimulants
IL88619A0 (en) * 1987-12-15 1989-07-31 Pfizer Non-peptidic renin inhibitors
US5635527A (en) * 1994-06-06 1997-06-03 The Green Cross Corporation Carboxylic acid compound having condensed ring, salt thereof and pharmaceutical use thereof
JP3314938B2 (ja) * 1995-06-06 2002-08-19 ファイザー・インコーポレーテッド グリコーゲンホスホリラーゼ抑制剤としての置換されたｎ−（インドール−２−カルボニル）−グリシンアミド類および誘導体
FI974437A0 (fi) * 1995-06-06 1997-12-05 Pfizer Substituoituja N-(indoli-2-karbonyyli)amideja ja johdannaisia glykogeenifosforylaasi-inhibiittoreina
KR100241643B1 (ko) * 1995-06-06 2000-03-02 디. 제이. 우드 당뇨병치료제인 치환된 N-(인돌-2-카르보닐)-β-알라님아미드 및 그의 유도체
US5952322A (en) * 1996-12-05 1999-09-14 Pfizer Inc. Method of reducing tissue damage associated with non-cardiac ischemia using glycogen phosphorylase inhibitors
GB9902047D0 (en) * 1999-01-29 1999-03-17 Cerebrus Ltd Chemical compounds XI
DE60007592T2 (de) * 1999-09-30 2004-09-16 Pfizer Products Inc., Groton Bicyclische Pyrrolylamide als Glycogenphosphorylase-Inhibitoren
GB0021831D0 (en) * 2000-09-06 2000-10-18 Astrazeneca Ab Chemical compounds
GB0202015D0 (en) * 2002-01-29 2002-03-13 Hoffmann La Roche Piperazine Derivatives
BR0315681A (pt) * 2002-10-30 2005-09-06 Merck Frosst Canada Inc Composto e seus sais e hidratos farmaceuticamente aceitáveis, composição farmacêutica, métodos para o tratamento de doenças mediadas pela prostaglandina d2, para o tratamento de congestão nasal, para o tratamento de asma alérgica, e para o tratamento de rinite alérgica, composto ou um seu sal ou solvato farmaceuticamente aceitável, sal ou hidrato do composto, e, uso de um composto ou de um seu sal ou solvato farmaceuticamente aceitável

Also Published As

Publication number Publication date
JP5669691B2 (ja) 2015-02-12
WO2004104001A2 (en) 2004-12-02
JP2011252005A (ja) 2011-12-15
IL171851A (en) 2011-08-31
WO2004104001A3 (en) 2005-03-03
NO20055305D0 (no) 2005-11-10
UA84146C2 (ru) 2008-09-25
NZ543482A (en) 2009-02-28
MA27809A1 (fr) 2006-03-01
NO20055305L (no) 2005-12-15
EA009215B1 (ru) 2007-12-28
AU2004240946A1 (en) 2004-12-02
BRPI0410445B1 (pt) 2017-11-28
CA2525502C (en) 2012-12-18
CA2525502A1 (en) 2004-12-02
EP1636224A2 (de) 2006-03-22
MXPA05012547A (es) 2006-05-25
JP2006528702A (ja) 2006-12-21
AU2004240946B8 (en) 2012-01-12
EA200501645A1 (ru) 2006-06-30
AU2004240946B2 (en) 2011-09-08
KR20060069792A (ko) 2006-06-22
KR101120935B1 (ko) 2012-03-05
NO332265B1 (no) 2012-08-13
BRPI0410445A (pt) 2006-05-30
DE602004028122D1 (de) 2010-08-26
EP1636224B1 (de) 2010-07-14

Similar Documents

Publication Publication Date Title
DE602004028122D1 (de) Pyrrolopyridin-2-carbonsäuren als hemmer der glycogenphosphorylase
DK1088824T3 (da) Bicykliske pyrrolylamider som glycogen phosphorylase inhibitorer
JO2282B1 (en) Oxazole derivatives
TW200718424A (en) Novel compounds of amino sulfonyl derivatives
NO20081846L (no) Bifenylderivater og deres anvendelse ved behandling av hepatitt C
ATE405266T1 (de) Monozyklische oder bizyklische carbozyklen und heterozyklen als hemmer von factor xa
EA200500304A1 (ru) Производные 3-(сульфонамидоэтил)индола, предназначенные для использования в качестве миметиков глюкокортикоидов при лечении воспалительных, аллергических и пролиферативных заболеваний
EA200701808A1 (ru) Производные тетрагидроиндолона и тетрагидроиндазолона
ATE478047T1 (de) Indolderivate als viruzide
WO2010036613A8 (en) Novel cyclic benzimidazole derivatives useful anti-diabetic agents
DE602005023965D1 (de) Pyrrolopyridin-2-carbonsäurehydrazide als inhibitoren von glykogenphosphorylase
PE20060243A1 (es) Derivados de 4-amino insustituido-5-(4-urea-fenil)-pirrolotriazina
NO20072223L (no) Glykogenfosforylaseinhibitor forbindelser med farmsoytiske preparater av disse
CY1111693T1 (el) Αντιιικοι παραγοντες
CY1111425T1 (el) ΠΑΡΑΓΩΓΑ ΤΗΣ ΠΥΡΙΔΟ[2,1-a]-ΙΣΟΚΙΝΟΛΙΝΗΣ ΩΣ DPP-IV ΑΝΑΣΤΟΛΕΙΣ
DE60214198D1 (de) Isoxazolyl-pyrimidines als inhibitoren von src- und lck-protein-kinasen
NO20060664L (no) N-substituerte benzimidazolyl C-kit inhibitorer
ATE384058T1 (de) Thiazolderivate
NO20082445L (no) Neuropeptid-2 reseptor-agonister
DE60003863D1 (de) Dioxocyclopentylhydroxamsäure
DE602005013275D1 (de) Pyrrolopyridin-2-karbonsäureamide
NO20065260L (no) Tri(cyklo)substituerte amidforbindelser
NO20063576L (no) 1,3-dioksanederivativer og analoge forbindelser for behandling av fedme og diabetes
GEP20074058B (en) 4-(7-halo-2-quino(xa) linyloxy-phenoxy-propionic acid derivatives as antineoplastic agents
WO2005085194A3 (en) Indole-2-carboxylic acid hydrazides as glycogen phosphorylase inhibitors

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties